Heartflow (HTFL) announced Heartflow Plaque Analysis is now covered by Aetna across all lines of business, including Commercial, Medicare Advantage, and Aetna Better Health Medicaid plans. Aetna is the fourth major national commercial insurer to update its policies to cover Heartflow Plaque Analysis to fully align with the guidelines issued by radiology benefit manager EviCore, following similar decisions by Humana, Cigna, and UnitedHealthcare. Heartflow Plaque Analysis is covered for the majority of insured lives across the United States.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HTFL:
- Twelve new option listings and two option delistings on December 24th
- Insiders Step in on These 2 ‘Strong Buy’ Stocks — And Analysts Are on the Same Page
- ACC, AHA publish scientific statements supporting Heartflow plaque analysis
- Heartflow price target raised to $40 from $35 at Stifel
- Heartflow price target raised to $40 from $36 at JPMorgan
